Glioblastoma Multiforme: An Evaluation of Existing and Alternative Treatment Modalities
DOI:
https://doi.org/10.47611/jsrhs.v11i4.3586Keywords:
Glioblastoma Multiforme, Oncolytic Virotherapy, Photodynamic Therapy, Tumor Treatment Fields Therapy, Review, Alternative Treatment, Conventional TherapiesAbstract
Glioblastoma Multiforme is one of the most aggressive brain tumours with very poor prognosis, low progression free survival rates and overall survival rates. This is predominantly due to the difficulty in transporting drugs across the blood brain barrier. Therefore, the need for more efficacious treatments is increasing. This paper explains the pathophysiology behind how signal transduction pathways leading from faults in the EGFRvIII and the IDH gene lead to gliomagenesis. It moves on to highlight and contrast conventional therapies such as Surgical Resection, Chemotherapy, Bevacizumab and Radiotherapy with novel, alternative therapies such as oncolytic virotherapy, photodynamic therapy and tumour treatment fields. A literature review was also conducted, wherein methods and results - specifically, the phase of trial, number of patients, treatment modality, median progression free survival, median overall survival and general comments- of five past research studies were explicated and interpreted for each GBM alternative treatment modalities - Photodynamic therapy, oncolytic virotherapy and tumour treatment fields. Each of the 5 clinical trial studies for each alternative treatment yielded varied results: The mean mOS (median Overall Survival) and mPFS (median Progression Free Survival) of patients were 15.3 months and 7.5 months for OV, 18.4 months and 16 months for PDT, and 19.9 months and 6 months for TTF respectively. This paper intends to provide an insight into the future of Glioblastoma Multiforme treatment to further improve its diagnosis, prognosis and treatment.
Downloads
References or Bibliography
INTRODUCTION
Arévalo, Ángelo S.T.; Erices, José I.; Uribe, Daniel A.; Howden, Jake; Niechi, Ignacio; Muñoz, Sebastián; Martín, Rody S.; Monrás, Claudia A.Q. (2017). Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme. Current Medicinal Chemistry, 24(25), –. https://doi.org/10.2174/0929867324666170303122241
Bush, Nancy Ann Oberheim; Chang, Susan M.; Berger, Mitchel S. (2017). Current and future strategies for treatment of glioma. Neurosurgical Review, 40(1), 1–14. doi:https://doi.org/10.1007/s10143-016-0709-8
EPIDEMIOLOGY
Tamimi, A. F., & Juweid, M. (2017). Epidemiology and Outcome of Glioblastoma. In S. De Vleeschouwer (Ed.), Glioblastoma. Codon Publications.https://www.ncbi.nlm.nih.gov/books/NBK470003/
PATHOPHYSIOLOGY
Avellaneda Matteo, D., Grunseth, A. J., Gonzalez, E. R., Anselmo, S. L., Kennedy, M. A., Moman, P., Scott, D. A., Hoang, A., & Sohl, C. D. (2017). Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumours: The role of size and hydrophobicity at residue 132 on catalytic efficiency. The Journal of biological chemistry, 292(19), 7971–7983. https://doi.org/10.1074/jbc.M117.776179
Reiter-Brennan, C., Semmler, L., & Klein, A. (2018). The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas. Contemporary oncology (Poznan, Poland), 22(4), 215–222. https://doi.org/10.5114/wo.2018.82642
Hatanpaa, K. J., Burma, S., Zhao, D., & Habib, A. A. (2010). Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia (New York, N.Y.), 12(9), 675–684. https://doi.org/10.1593/neo.10688
PRESENT DIAGNOSES AND TREATMENTS
Wang, L., Liang, B., Li, Y.I. et al. What is the advance of extent of resection in glioblastoma surgical treatment—a systematic review. Chin Neurosurg Jl 5, 2 (2019). https://doi.org/10.1186/s41016-018-0150-7
Barani, I. J., & Larson, D. A. (2015). Radiation therapy of glioblastoma. Cancer treatment and research, 163, 49–73. https://doi.org/10.1007/978-3-319-12048-5_4
https://moffitt.org/cancers/glioblastoma/treatment/radiation/
Pashaki, A. S., Hamed, E. A., Mohamadian, K., Abassi, M., Safaei, A. M., & Torkaman, T. (2014). Efficacy of high dose radiotherapy in post-operative treatment of glioblastoma multiforme--a single institution report. Asian Pacific journal of cancer prevention : APJCP, 15(6), 2793–2796. https://doi.org/10.7314/apjcp.2014.15.6.279
Bush, N.A.O., Chang, S.M. & Berger, M.S. Current and future strategies for treatment of glioma. Neurosurg Rev 40, 1–14 (2017). https://doi.org/10.1007/s10143-016-0709-8
Marina, O., Suh, J. H., Reddy, C. A., Barnett, G. H., Vogelbaum, M. A., Peereboom, D. M., Stevens, G. H., Elinzano, H., & Chao, S. T. (2011). Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. Journal of neurosurgery, 115(2), 220–229. https://doi.org/10.3171/2011.3.JNS10495
BEVACIZUMAB
Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. (2010). Bevacizumab. The oncologist, 15(8), 819–825. https://doi.org/10.1634/theoncologist.2009-0317
Olofsson, B., Korpelainen, E., Pepper, M. S., Mandriota, S. J., Aase, K., Kumar, V., Gunji, Y., Jeltsch, M. M., Shibuya, M., Alitalo, K., & Eriksson, U. (1998). Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 95(20), 11709–11714. https://doi.org/10.1073/pnas.95.20.11709
Carmeliet P. (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology, 69 Suppl 3, 4–10. https://doi.org/10.1159/000088478
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., Jeraj, R., Brown, P. D., Jaeckle, K. A., Schiff, D., Stieber, V. W., Brachman, D. G., Werner-Wasik, M., Tremont-Lukats, I. W., Sulman, E. P., Aldape, K. D., … Mehta, M. P. (2014). A randomised trial of bevacizumab for newly diagnosed glioblastoma. The New England journal of medicine, 370(8), 699–708. https://doi.org/10.1056/NEJMoa1308573 - BAD STUDY
Babu, R., Komisarow, J. M., Agarwal, V. J., Rahimpour, S., Iyer, A., Britt, D., Karikari, I. O., Grossi, P. M., Thomas, S., Friedman, A. H., & Adamson, C. (2016). Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. Journal of neurosurgery, 124(4), 998–1007. https://doi.org/10.3171/2015.4.JNS142200 - Babus study
Lyon, K. A., & Huang, J. H. (2018). Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts. Translational cancer research, 7(Suppl 7), S802–S805. https://doi.org/10.21037/tcr.2018.08.19
ALTERNATIVE THERAPIES
ONCOLYTIC VIROTHERAPY
E Antonio Chiocca, Farshad Nassiri, Justin Wang, Pierpaolo Peruzzi, Gelareh Zadeh, Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?, Neuro-Oncology, Volume 21, Issue 1, January 2019, Pages 14–25, https://doi.org/10.1093/neuonc/noy170
Stavrakaki, E., Dirven, C., & Lamfers, M. (2021). Personalising Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response. Cancers, 13(4), 614. https://doi.org/10.3390/cancers13040614
Martikainen, M., & Essand, M. (2019). Virus-Based Immunotherapy of Glioblastoma. Cancers, 11(2), 186. https://doi.org/10.3390/cancers11020186
Wollmann, Guido & Özduman, Koray & Pol, Anthony. (2012). Oncolytic Virus Therapy for Glioblastoma Multiforme. Cancer journal (Sudbury, Mass.). 18. 69-81. https://doi.org/10.1097/PPO.0b013e31824671c9 Gesundheit, B., Ben-David, E., Posen, Y., Ellis, R., Wollmann, G., Schneider, E. M., Aigner, K., Brauns, L., Nesselhut, T., Ackva, I., Weisslein, C., & Thaller, A. (2020). Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series. Frontiers in oncology, 10, 702. https://doi.org/10.3389/fonc.2020.00702
PHOTODYNAMIC THERAPY
Bauer G. (2016). The Antitumor Effect of Singlet Oxygen. Anticancer research, 36(11), 5649–5663. https://doi.org/10.21873/anticanres.11148
Cramer, S. W., & Chen, C. C. (2020). Photodynamic Therapy for the Treatment of Glioblastoma. Frontiers in surgery, 6, 81. https://doi.org/10.3389/fsurg.2019.00081
Abrahamse, H., & Hamblin, M. R. (2016). New photosensitizers for photodynamic therapy. The Biochemical journal, 473(4), 347–364. https://doi.org/10.1042/BJ20150942
Perillo, B., Di Donato, M., Pezone, A. et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med 52, 192–203 (2020). https://doi.org/10.1038/s12276-020-0384-2
Hawk, M. A., & Schafer, Z. T. (2018). Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. The Journal of biological chemistry, 293(20), 7531–7537. https://doi.org/10.1074/jbc.TM117.000260
TUMOUR TREATMENT FIELDS
Zhu, P., & Zhu, J. J. (2017). Tumour treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. Chinese clinical oncology, 6(4), 41. https://doi.org/10.21037/cco.2017.06.29
Israeli Medicine – chosen for excellence. (2020, February 11). OPTUNE wearable device by Novocure Video]. YouTube. https://www.youtube.com/watch?v=i1lX32-HwP0&feature=youtu.be
CLINICAL TRIALS AND RESULTS
ONCOLYTIC VIROTHERAPY
Desjardins, A., Gromeier, M., Herndon, J. E., 2nd, Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., Peters, K. B., Randazzo, D., Sampson, J. H., Vlahovic, G., Harrison, W. T., McLendon, R. E., Ashley, D., & Bigner, D. D. (2018). Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England journal of medicine, 379(2), 150–161. https://doi.org/10.1056/NEJMoa1716435
https://pubmed.ncbi.nlm.nih.gov/34214495/ - Fares, J., Ahmed, A. U., Ulasov, I. V., Sonabend, A. M., Miska, J., Lee-Chang, C., Balyasnikova, I. V., Chandler, J. P., Portnow, J., Tate, M. C., Kumthekar, P., Lukas, R. V., Grimm, S. A., Adams, A. K., Hébert, C. D., Strong, T. V., Amidei, C., Arrieta, V. A., Zannikou, M., Horbinski, C., … Lesniak, M. S. (2021). Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. The Lancet. Oncology, 22(8), 1103–1114. https://doi.org/10.1016/S1470-2045(21)00245-X
Todo, T., Ino, Y., Ohtsu, H., Shibahara, J., & Tanaka, M. (2022). A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. Nature communications, 13(1), 4119. https://doi.org/10.1038/s41467-022-31262-y
https://pubmed.ncbi.nlm.nih.gov/15452186/ - Steiner, H. H., Bonsanto, M. M., Beckhove, P., Brysch, M., Geletneky, K., Ahmadi, R., Schuele-Freyer, R., Kremer, P., Ranaie, G., Matejic, D., Bauer, H., Kiessling, M., Kunze, S., Schirrmacher, V., & Herold-Mende, C. (2004). Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22(21), 4272–4281. https://doi.org/10.1200/JCO.2004.09.038
Geletneky, K., Hajda, J., Angelova, A. L., Leuchs, B., Capper, D., Bartsch, A. J., Neumann, J. O., Schöning, T., Hüsing, J., Beelte, B., Kiprianova, I., Roscher, M., Bhat, R., von Deimling, A., Brück, W., Just, A., Frehtman, V., Löbhard, S., Terletskaia-Ladwig, E., Fry, J., … Rommelaere, J. (2017). Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. Molecular therapy : the journal of the American Society of Gene Therapy, 25(12), 2620–2634. https://doi.org/10.1016/j.ymthe.2017.08.016
PHOTODYNAMIC THERAPY
https://pubmed.ncbi.nlm.nih.gov/23952800/ - Muragaki, Y., Akimoto, J., Maruyama, T., Iseki, H., Ikuta, S., Nitta, M., Maebayashi, K., Saito, T., Okada, Y., Kaneko, S., Matsumura, A., Kuroiwa, T., Karasawa, K., Nakazato, Y., & Kayama, T. (2013). Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumours. Journal of neurosurgery, 119(4), 845–852. https://doi.org/10.3171/2013.7.JNS13415
Vermandel, M., Dupont, C., Lecomte, F., Leroy, H. A., Tuleasca, C., Mordon, S., Hadjipanayis, C. G., & Reyns, N. (2021). Standardised intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial. Journal of neuro-oncology, 152(3), 501–514. https://doi.org/10.1007/s11060-021-03718-6
https://pubmed.ncbi.nlm.nih.gov/22594978/ - Akimoto, J., Haraoka, J., & Aizawa, K. (2012). Preliminary clinical report on safety and efficacy of photodynamic therapy using talaporfin sodium for malignant gliomas. Photodiagnosis and photodynamic therapy, 9(2), 91–99. https://doi.org/10.1016/j.pdpdt.2012.01.001
https://pubmed.ncbi.nlm.nih.gov/17926079/ - Eljamel, M. S., Goodman, C., & Moseley, H. (2008). ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers in medical science, 23(4), 361–367. https://doi.org/10.1007/s10103-007-0494-2
https://pubmed.ncbi.nlm.nih.gov/16788926/ - Muller, P. J., & Wilson, B. C. (2006). Photodynamic therapy of brain tumours--a work in progress. Lasers in surgery and medicine, 38(5), 384–389. https://doi.org/10.1002/lsm.20338
TUMOUR TREATMENT FIELDS
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., Di Meco, F., Lieberman, F., Zhu, J. J., Stragliotto, G., Tran, D., Brem, S., Hottinger, A., Kirson, E. D., Lavy-Shahaf, G., Weinberg, U., … Ram, Z. (2017). Effect of Tumour-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomised Clinical Trial. JAMA, 318(23), 2306–2316. https://doi.org/10.1001/jama.2017.18718
Kim, C. Y., Paek, S. H., Nam, D. H., Chang, J. H., Hong, Y. K., Kim, J. H., Kim, O. L., & Kim, S. H. (2020). Tumour treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. Journal of neuro-oncology, 146(3), 399–406. https://doi.org/10.1007/s11060-019-03361-2
Ballo, M. T., Urman, N., Lavy-Shahaf, G., Grewal, J., Bomzon, Z., & Toms, S. (2019). Correlation of Tumour Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomised Trial. International journal of radiation oncology, biology, physics, 104(5), 1106–1113. https://doi.org/10.1016/j.ijrobp.2019.04.008
Kesari, S., Ram, Z., & EF-14 Trial Investigators (2017). Tumour-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. CNS oncology, 6(3), 185–193. https://doi.org/10.2217/cns-2016-0049
Published
How to Cite
Issue
Section
Copyright (c) 2022 Sriram Seshadri, Mithun Makam, Rishab Makam; Shalav Kakati
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
